Role of endothelin in cardiovascular disease

@article{Agapitov2002RoleOE,
  title={Role of endothelin in cardiovascular disease},
  author={Alexei V. Agapitov and William G. Haynes},
  journal={Journal of the Renin-Angiotensin-Aldosterone System},
  year={2002},
  volume={3},
  pages={1 - 15}
}
Endothelins are a family of peptides, which comprises endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3), each containing 21 amino-acids. ET-1 is a peptide secreted mostly by vascular endothelial cells, the predominant isoform expressed in vasculature and the most potent vasoconstrictor currently known. ET-1 also has inotropic, chemotactic and mitogenic properties. In addition, it influences salt and water homeostasis through its effects on the renin-angiotensin-aldosterone system… 
View on SAGE
departamentos.cardiol.br
190 Citations
Highly Influential Citations
9
Background Citations
82
Methods Citations
3
Results Citations
1

Figures and Tables from this paper

190 Citations

Endothelin antagonists in hypertension and kidney disease

Experimental evidence and recent clinical studies suggest that endothelin receptor blockade, in particular selective ETAR blockade, holds promise in the treatment of hypertension, proteinuria, and diabetes.

Endothelin ETA receptor antagonism in cardiovascular disease.

Pathophysiological roles of endothelin receptors in cardiovascular diseases.

The current understanding regarding the role of ET receptors, especially the ET(B) receptor, in CVD is summarized.

Role of endothelin in uteroplacental circulation and fetal vascular function.

Endothelins are 21-amino acid peptides involved in vascular homeostasis, and endothelin-1 (ET-1) being the most potent vasoconstrictor currently known is observed in hypertension and preeclampsia in pregnancy.

Endothelin Antagonism Suppresses Plasma and Cardiac Endothelin-1 Levels in SHRSPs at the Typical Hypertensive Stage

Investigation of the effects of ET blockade on the expression levels of plasma and cardiac ET-1 in SHRSPs found that suppression of the upregulated ET system might be beneficial in arresting cardiac remodeling.

Endothelin Receptor Blockers in Cardiovascular Disease

The endothelin (ET) system is comprised of 4 active ETs, with ET-1 being the predominant isoform in the cardiovascular system, and the nonselective ET receptor antagonist bosentan improves exercise capacity and increases time to clinical worsening in patients with pulmonary arterial hypertension.

Inhibition of ENaC by endothelin-1.

Endothelin-1 and H2O2-induced signaling in vascular smooth muscle cells : modulation by CaMKII and Nitric oxide

A role of CaMKII in mediatingET-1 and H2O2induced ERK1/2, PKB, Pyk2 phosphorylation, as well as its effect on hypertrophic and proliferative responses of ET-1 in VSMCs remains unexplored.

Vascular Endothelin and Angiotensin Receptors Regulation in Inflammatory Arterial Disorders

It is demonstrated that there is increased ETB and AT1 receptor expression in VSMC in ischemic heart disease and in GCA which correlates with the degree of inflammation.

Expression of Endothelin-1 by Stimulation with CXCL8 in Mouse Peritoneal Macrophages

Investigation of the role of IL-8/CXCL8, as a major inflammatory chemokine, for ET-1 expression in macrophges suggests it can act as one of main inducers ofET-1 in vascular inflammatory reactions, and ET- 1 expression by IL- 8/CxCL8 is related to 12-LO pathway in PeMφ.
...

References

SHOWING 1-10 OF 201 REFERENCES

Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology.

According to this study, endothelin-1 participates in volume homeostasis in human, whereas pathophysiological concentrations can contribute to renal vasoconstriction and sodium retention, and calcium channel blockers may protect against these effects of endothelins-1.

Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension.

It is indicated that TAK-044 caused a greater degree of vasodilation in the forearm vessels of essential hypertensive patients compared with normotensive subjects, an alteration associated with decreased tonic NO release.

Contribution of endogenous generation of endothelin-1 to basal vascular tone

Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.

The role for ET-1 in the pathogenesis of endothelial function is supported, and endothelin receptor antagonists may have a therapeutic role by maintaining coronary endothelialfunction in pathophysiological states.

Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist.

BACKGROUND In vitro studies on vascular smooth muscle cells suggest that endothelin has a stimulating effect on cellular proliferation. This study was designed to determine the endogenous effect of…

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

Preliminary results suggest that pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endethelin- 1 may contribute to the vascular abnormalities associated with this disorder.

Plasma Endothelin in Chronic Heart Failure

Evidence suggests that circulatory endothelin concentrations in the range 5–40 pmol/l are vasoactive, and may be of pathophysiological significance in patients with chronic heart failure.

Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.

In conclusion, endogenous endothelin contributes to the cardiovascular and renal effects of Ang II, and the dipsogenic action of angiotensin II was not influenced by bosentan.

Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.

Endogenous endothelin exerts a vasoconstrictor tone in epicardial coronary arteries of patients with coronary artery disease, as evidenced by the vasodilation exerted by the combined ETA/ETB endothelins-receptor antagonist bosentan under acute conditions.

Selective upregulation of endothelin converting enzyme-1a in the human failing heart.

This study showed that the biosynthetic pathway of ET-1 is activated in LV myocardium in the failing heart, and the myocardial processing of big ET- 1 is highly specific for ECE-1.
...